<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en"><head><meta http-equiv="Content-Type" content="text/html; charset=UTF-8" /><meta http-equiv="Content-Language" content="en" /><title>Verbatim report of proceedings - Innovative Medicines Initiative 2 Joint Undertaking (A7-0105/2014 - Teresa Riera Madurell) - Tuesday, 15 April 2014</title><meta name="title" content="Verbatim report of proceedings - Innovative Medicines Initiative 2 Joint Undertaking (A7-0105/2014 - Teresa Riera Madurell) - Tuesday, 15 April 2014" /><meta name="language" content="en" /><meta name="robots" content="index, follow, noodp, noydir, notranslate" /><meta name="copyright" content="© European Union, 2014 - Source: European Parliament" /><meta name="available" content="15-04-2014" /><meta name="sipade-leg" content="7" /><meta name="sipade-type" content="CRE" /><meta property="og:title" content="Verbatim report of proceedings - Innovative Medicines Initiative 2 Joint Undertaking (A7-0105/2014 - Teresa Riera Madurell) - Tuesday, 15 April 2014" /><meta property="og:image" content="https://www.europarl.europa.eu/website/common/img/icon/sharelogo_facebook.jpg" /><link rel="canonical" href="https://www.europarl.europa.eu/doceo/document/CRE-7-2014-04-15-ITM-009-34_EN.html" /><link href="/doceo/data/css/style_common.css" rel="stylesheet" type="text/css" /><link href="/doceo/data/css/style_common_print.css" rel="stylesheet" type="text/css" /><link href="/doceo/data/css/style_sipade.css" rel="stylesheet" type="text/css" /><link href="/doceo/data/css/style_activities.css" rel="stylesheet" type="text/css" /><link href="/doceo/data/css/common_sides.css" type="text/css" rel="stylesheet" /><link href="/doceo/data/css/style_sipade_oj_sched.css" type="text/css" rel="stylesheet" />
<script src="/doceo/data/js/overlib.js" type="text/javascript"> </script>
<script src="/doceo/data/js/swap_images.js" type="text/javascript"> </script>
<script src="/doceo/data/js/sipade.js" type="text/javascript"> </script>
<script src="/doceo/data/js/jquery-1.4.4.js" type="text/javascript"> </script>
<script src="/doceo/data/js/sipade-OJ-SYN.js" type="text/javascript"> </script><!--ATI analytics script--><script type="text/javascript" data-tracker-name="ATInternet" defer data-value="/website/webanalytics/ati-doceo.js" src="//www.europarl.europa.eu/website/privacy-policy/privacy-policy.js" ></script></head><body bgcolor="#FFFFFF"><div id="overDiv" style="position:absolute; visibility:hidden; z-index:1000;"> </div><a name="top"></a><table cellpadding="0" cellspacing="0" border="0" width="100%"><tr><td><div id="header_sides" class="new">
<a href="/portal/en"><img alt="Go back to the Europarl portal" title="Go back to the Europarl portal" src="/doceo/data/img/EP_logo_neg_EN.png" /></a><h3 class="ep_hidden">Choisissez la langue de votre document :</h3><ul class="language_select">
            <li><a title="bg - български" class="bg on" href="/doceo/document/CRE-7-2014-04-15-ITM-009-34_BG.html">bg - български</a></li>
            <li><a title="es - español" class="es on" href="/doceo/document/CRE-7-2014-04-15-ITM-009-34_ES.html">es - español</a></li>
            <li><a title="cs - čeština" class="cs on" href="/doceo/document/CRE-7-2014-04-15-ITM-009-34_CS.html">cs - čeština</a></li>
            <li><a title="da - dansk" class="da on" href="/doceo/document/CRE-7-2014-04-15-ITM-009-34_DA.html">da - dansk</a></li>
            <li><a title="de - Deutsch" class="de on" href="/doceo/document/CRE-7-2014-04-15-ITM-009-34_DE.html">de - Deutsch</a></li>
            <li><a title="et - eesti keel" class="et on" href="/doceo/document/CRE-7-2014-04-15-ITM-009-34_ET.html">et - eesti keel</a></li>
            <li><a title="el - ελληνικά" class="el on" href="/doceo/document/CRE-7-2014-04-15-ITM-009-34_EL.html">el - ελληνικά</a></li>
            <li class="en selected" title="en - English">en - English<span> (Selected)</span></li>
            <li><a title="fr - français" class="fr on" href="/doceo/document/CRE-7-2014-04-15-ITM-009-34_FR.html">fr - français</a></li>
            <li class="ga" title="ga - Gaeilge">ga - Gaeilge</li>
            <li><a title="hr - hrvatski" class="hr on" href="/doceo/document/CRE-7-2014-04-15-ITM-009-34_HR.html">hr - hrvatski</a></li>
            <li><a title="it - italiano" class="it on" href="/doceo/document/CRE-7-2014-04-15-ITM-009-34_IT.html">it - italiano</a></li>
            <li><a title="lv - latviešu valoda" class="lv on" href="/doceo/document/CRE-7-2014-04-15-ITM-009-34_LV.html">lv - latviešu valoda</a></li>
            <li><a title="lt - lietuvių kalba" class="lt on" href="/doceo/document/CRE-7-2014-04-15-ITM-009-34_LT.html">lt - lietuvių kalba</a></li>
            <li><a title="hu - magyar" class="hu on" href="/doceo/document/CRE-7-2014-04-15-ITM-009-34_HU.html">hu - magyar</a></li>
            <li><a title="mt - Malti" class="mt on" href="/doceo/document/CRE-7-2014-04-15-ITM-009-34_MT.html">mt - Malti</a></li>
            <li><a title="nl - Nederlands" class="nl on" href="/doceo/document/CRE-7-2014-04-15-ITM-009-34_NL.html">nl - Nederlands</a></li>
            <li><a title="pl - polski" class="pl on" href="/doceo/document/CRE-7-2014-04-15-ITM-009-34_PL.html">pl - polski</a></li>
            <li><a title="pt - português" class="pt on" href="/doceo/document/CRE-7-2014-04-15-ITM-009-34_PT.html">pt - português</a></li>
            <li><a title="ro - română" class="ro on" href="/doceo/document/CRE-7-2014-04-15-ITM-009-34_RO.html">ro - română</a></li>
            <li><a title="sk - slovenčina" class="sk on" href="/doceo/document/CRE-7-2014-04-15-ITM-009-34_SK.html">sk - slovenčina</a></li>
            <li><a title="sl - slovenščina" class="sl on" href="/doceo/document/CRE-7-2014-04-15-ITM-009-34_SL.html">sl - slovenščina</a></li>
            <li><a title="fi - suomi" class="fi on" href="/doceo/document/CRE-7-2014-04-15-ITM-009-34_FI.html">fi - suomi</a></li>
            <li><a title="sv - svenska" class="sv on" href="/doceo/document/CRE-7-2014-04-15-ITM-009-34_SV.html">sv - svenska</a></li>
        </ul></div></td></tr><tr><td style="padding:10px;"><table width="100%" border="0" cellspacing="0" cellpadding="0"><tr><td><table border="0" align="left" cellpadding="0" cellspacing="0"><tr><td><table border="0" cellspacing="0" cellpadding="0" class="buttondocwin"><tr><td><a href="/doceo/document/CRE-7-2014-04-15-TOC_EN.html"><img src="/doceo/data/img/navi_index.gif" width="16" height="16" border="0" align="absmiddle" alt="" /></a></td><td valign="middle"> <a href="/doceo/document/CRE-7-2014-04-15-TOC_EN.html" title="Index">Index</a> </td></tr></table></td><td><img src="/doceo/data/img/spacer.gif" width="10" height="8" alt="" /></td><td><table border="0" cellspacing="0" cellpadding="0" class="buttondocwin"><tr><td><a href="/doceo/document/CRE-7-2014-04-15-ITM-009-33_EN.html"><img src="/doceo/data/img/navi_previous.gif" width="16" height="16" border="0" align="absmiddle" alt="" /></a></td><td valign="middle"> <a href="/doceo/document/CRE-7-2014-04-15-ITM-009-33_EN.html" title="Previous">Previous</a> </td></tr></table></td><td><img src="/doceo/data/img/spacer.gif" width="10" height="8" alt="" /></td><td><table border="0" cellspacing="0" cellpadding="0" class="buttondocwin"><tr><td valign="middle"> <a href="/doceo/document/CRE-7-2014-04-15-ITM-009-35_EN.html" title="Next">Next</a> </td><td><a href="/doceo/document/CRE-7-2014-04-15-ITM-009-35_EN.html"><img src="/doceo/data/img/navi_next.gif" width="16" height="16" border="0" align="absmiddle" alt="" /></a></td></tr></table></td><td><img src="/doceo/data/img/spacer.gif" width="10" height="8" alt="" /></td><td><table border="0" cellspacing="0" cellpadding="0" class="buttondocwin"><tr><td><a href="/doceo/document/CRE-7-2014-04-15_EN.html"><img src="/doceo/data/img/navi_moredetails.gif" width="16" height="16" border="0" align="absmiddle" alt="" /></a></td><td valign="middle"> <a href="/doceo/document/CRE-7-2014-04-15_EN.html" title="Full text">Full text</a> </td></tr></table></td><td><img src="/doceo/data/img/spacer.gif" width="10" height="8" alt="" /></td></tr><tr><td><img src="/doceo/data/img/spacer.gif" width="10" height="15" alt="" /></td></tr></table></td></tr></table>
                <table border="0" cellpadding="0" cellspacing="0" width="100%"><tbody><tr><td align="left"><span class="contents">Procedure : </span><a class="ring_ref_link" href="https://oeil.secure.europarl.europa.eu/oeil/popups/ficheprocedure.do?lang=en&amp;reference=2013/0240(NLE)">2013/0240(NLE)</a></td><td align="right"><table align="right" border="0" cellpadding="0" cellspacing="0"><tbody><tr><td><img src="/doceo/data/img/ring_tabs_left_doc_unselected.gif" height="19" width="4" alt="" /></td><td class="Tabs_doc_unselected"><img src="/doceo/data/img/ring_navi.gif" width="17" height="14" alt="" />Document stages in plenary</td><td valign="middle"><img src="/doceo/data/img/ring_tabs_right_doc_unselected.gif" height="19" width="4" alt="" /></td></tr></tbody></table></td></tr></tbody></table><table class="doc_box_header" border="0" cellpadding="0" cellspacing="0" width="100%"><tbody><tr><td class="ring_multiple_bg" valign="top" colspan="7">Document selected :
            <span class="ring_ref_selected_header">A7-0105/2014</span></td></tr><tr><td width="25%" valign="top" class="ring_step_bg1" nowrap="nowrap"><p class="ring_step_title">Texts tabled :</p>
                        <a href="/doceo/document/A-7-2014-0105_EN.html" class="ring_ref_link">A7-0105/2014</a><br />
                    </td><td width="15" style="background-image:url(/doceo/data/img/ring_bg1.gif)"><img src="/doceo/data/img/ring_flech1.gif" height="22" width="13" border="0" alt="" /></td><td class="ring_step_bg2" valign="top" width="25%" nowrap="nowrap"><p class="ring_step_title">Debates :</p></td><td width="15" style="background-image:url(/doceo/data/img/ring_bg2.gif)"><img src="/doceo/data/img/ring_flech2.gif" width="13" height="22" border="0" alt="" /></td><td class="ring_step_bg3" valign="top" width="25%" nowrap="nowrap"><p class="ring_step_title">Votes :</p>
                        <a href="/doceo/document/PV-7-2014-04-15-ITM-008-33_EN.html" class="ring_ref_link">PV 15/04/2014 - 8.33</a><br />
                        <a class="ring_ref_selected">Explanations of votes</a><br />
                    </td><td width="19" style="background-image:url(/doceo/data/img/ring_bg3.gif)"><img src="/doceo/data/img/ring_flech3.gif" height="22" width="13" border="0" alt="" /></td><td class="ring_step_bg4" valign="top" width="25%" nowrap="nowrap"><p class="ring_step_title">Texts adopted :</p>
                        <a href="/doceo/document/TA-7-2014-0373_EN.html" class="ring_ref_link">P7_TA(2014)0373</a><br />
                    </td></tr></tbody></table><br />
            <table width="100%" border="0" cellpadding="5" cellspacing="0" class="doc_box_header">
<tr>
<td align="left" valign="top" style="background-image:url(/doceo/data/img/gradient_blue.gif)" class="title_TA">Verbatim report of proceedings</td><td valign="top" align="right" style="background-image:url(/doceo/data/img/gradient_blue.gif)"></td>
</tr>
<tr>
<td class="doc_title" align="left" valign="top" bgcolor="#F5F5F5">Tuesday, 15 April 2014 - Strasbourg</td>
<td class="doc_title" align="right" valign="top" bgcolor="#F5F5F5">Revised edition</td></tr></table><br />
<table width="100%" border="0" cellpadding="0" cellspacing="0" class="doc_box_header" style="padding-bottom:5px"><tr valign="top"><td>
<table width="100%" border="0" cellpadding="5" cellspacing="0"><tr valign="top" style="padding-bottom:0px;padding-left:5px;padding-right:5px;padding-top:5px"><td align="left" style="background-image:url(/doceo/data/img/gradient_blue.gif)" class="doc_title"><img src="/doceo/data/img/arrow_title_doc.gif" width="8" height="14" border="0" align="absmiddle" alt="" /> 9.34. Innovative Medicines Initiative 2 Joint Undertaking (<a href="/doceo/document/A-7-2014-0105_EN.html">A7-0105/2014</a> - Teresa Riera Madurell) </td></tr></table>
<a name="2-615-000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><span class="bold">Dichiarazioni di voto scritte</span></p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-615-250"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/118860.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Claudette Abela Baldacchino (S&amp;D), </span></span>  <span class="italic">in writing</span><span class="bold">. - </span>The Innovative Medicines Initiative 2 (IMI2) will be the successor of IMI1, a Joint Technology Initiative set up under the 7th Framework Programme but with a different scope: from pre-competitive biomedical research the focus will shift to public health. By doing so, IMI2 will widen its agenda to encompass the whole cycle of innovation, bringing on board other life science industries, and covering not only research, but also the commercialisation of innovative medicines.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-615-375"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/96976.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Luís Paulo Alves (S&amp;D), </span></span>  <span class="italic">por escrito</span>. <span class="bold">-</span> Aprovo o presente Relatório, considerando que a Iniciativa sobre Medicamentos Inovadores 2 será a sucessora da IMI-1, uma Iniciativa Tecnológica Conjunta criada ao abrigo do 7.º Programa-Quadro. Louvo o facto de que este terá um âmbito diferente: deixa de estar centrada na investigação biomédica pré-concorrencial para passar a centrar-se na saúde pública. Na prática, a IMI-2 alarga a sua agenda e passa a englobar todo o ciclo da inovação, incorporando outras indústrias das ciências da vida e abrangendo não apenas a investigação, mas também a comercialização de medicamentos inovadores. Como refere o segundo relatório intercalar sobre a IMI-1, houve um processo de aprendizagem, natural em qualquer regime novo, que se refletiu na presente proposta. Contudo, acredito que, em algumas questões, ainda existe margem para melhorar, nomeadamente ao garantir um melhor alinhamento com o Horizonte 2020 e promover uma estrutura de governação mais transparente, responsável e participativa.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-615-500"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/97198.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Mara Bizzotto (EFD), </span></span>  <span class="italic">per iscritto. - </span>Condivido la proposta di regolamento relativo all'impresa comune per l'iniziativa in materia di medicinali innovativi, trovo il testo equilibrato e ritengo che persegua al meglio gli obiettivi di interesse pubblico in questo settore particolarmente delicato, per questi motivi ho inteso votare a favore.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-615-750"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/96849.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Alain Cadec (PPE), </span></span>  <span class="italic">par écrit. </span><span class="bold"><span class="italic">– </span></span>J'ai voté en faveur du rapport Madurell concernant la mise en place de la deuxième initiative médicaments innovants pour la période 2014-2024. IMI2 est une initiative technologique conjointe mise en place au titre du 7<span class="sup">e</span> programme-cadre. Son champ d'application est élargi: l'accent est mis non plus sur la recherche biomédicale pré-concurrentielle (IMI1), mais sur la santé publique.</p>
<p class="contents">Ce partenariat public-privé entre la Commission européenne et l'industrie pharmaceutique vise à améliorer le processus de mise au point de médicaments innovants et de nouveaux traitements. Dans le cadre des négociations sur le paquet Horizon 2020, le Parlement européen a appliqué les recommandations du groupe d'experts sur l'évaluation intermédiaire du septième programme-cadre et du rapport d'audit du Parlement européen. L'IMI 2 inclura l'ensemble du cycle d'innovation et portera sur la recherche mais aussi sur la commercialisation des médicaments innovants.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-615-875"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/72775.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Rachida Dati (PPE), </span></span>  <span class="italic">par écrit</span><span class="bold">. –</span> L'objet de ce texte est la création d'une entreprise commune Médicaments innovants 2 dont le but est notamment l'amélioration des essais cliniques des médicaments prioritaires effectués au sein de l'Union. Elle prend le relais d'une entreprise commune existant dans le cadre du cadre financier précédent et réaffirme par la même occasion la nécessité de prendre des mesures courageuses dans le domaine de la santé publique. C'est ce qui est entrepris ici en encourageant la recherche pour de nouveaux traitements pour lesquels la demande est importante mais les avancées scientifiques sont lentes, comme la maladie d'Alzheimer.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-615-937"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/4550.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Jill Evans (Verts/ALE), </span></span>  <span class="italic">in writing</span><span class="bold">. -</span> I voted against this report as it provides for public subsidies to big pharmaceutical companies without containing any obligations or mechanisms for ensuring public sector return, such as access to research data, accessibility and affordability of medicines. In Wales we need to make scientific expertise and information available to health professionals.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-616-000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/119875.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Iñaki Irazabalbeitia Fernández (Verts/ALE), </span></span>  <span class="italic">por escrito</span><span class="bold">. -</span> He votado en contra porque soy de la opinión de que el informe es demasiado favorable a las grandes empresas del sector y, por ejemplo, no contiene ninguna condición para el acceso a los fondos de creación de empleo en Europa. Las pequeñas empresas del sector resultarán también perjudicadas en el acceso a fondos I+D y seguramente tendrán que actuar de subcontratistas de las grandes empresas.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-616-500"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/96884.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Philippe Juvin (PPE), </span></span>  <span class="italic">par écrit</span><span class="bold">. –</span> J'ai voté en faveur du rapport de ma collègue Teresa Riera Madurell qui propose la création de partenariats public-privé sur la base de l'entreprise commune Initiative en matière de médicaments innovants qui avait été établie sous le septième programme de recherche. Cette nouvelle version, conçue pour fonctionner dans le cadre du Cadre Horizon 2020, a pour objectif d'améliorer le développement de nouveaux médicaments en soutenant la coopération entre universitaires, PME et industrie pharmaceutique. Le texte a été adopté à une large majorité, ce dont je me félicite.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-616-750"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/96824.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Monica Luisa Macovei (PPE), </span></span>  <span class="italic">in writing</span><span class="bold">. - </span>I welcome the request for further transparency included in the report on the Innovative Medicines Initiative 2 Joint Undertaking. However, I would request more. The Joint Undertaking should make public the professional details of its managerial staff members, the Management Board members and the experts it employs. In addition, contact details and declarations of interest should be available on the Joint Undertakingʼs website. I call therefore on Innovative Medicines Initiative 2 to remedy the situation as a matter of urgency. This is the only way to offer full transparency, limit the risks of conflicts of interest and protect taxpayersʼ money invested in the research projects. I ask the Commission to closely monitor the system through which the Joint Undertaking chooses the projects and institutions which will receive funding from the European Union.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-616-875"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/96742.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Jean-Luc Mélenchon (GUE/NGL), </span></span>  <span class="italic">par écrit</span><span class="bold">. –</span> Le rapport met l'accent pour une fois sur la santé publique et non plus sur la recherche biomédicale concurrentielle. Il vise à favoriser la mise au point de produits traitant les maladies négligées et celles liées à la pauvreté. Pour ce faire, il propose d'impliquer davantage la communauté de chercheurs dans l'élaboration de programmes stratégiques de recherche. Mais évidemment le modèle favorisé est celui des partenariats public-privé et le budget initialement prévu a été revu à la baisse. </p>
<p class="contents">Les bonnes intentions européennes sont toujours pourries par l'argent. Je m'abstiens.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-617-000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/118859.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Roberta Metsola (PPE), </span></span>  <span class="italic">in writing</span><span class="bold">. - </span>We need to be able to continue to deliver better and safer medicines for patients. I voted in favour of this report as it improves the drug development process by supporting more efficient research and development cooperation among academia, small and medium enterprises and the biopharmaceutical industry.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-618-000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/118858.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Marlene Mizzi (S&amp;D), </span></span>  <span class="italic">in writing</span><span class="bold">. -</span> It is a positive sign that we are producing innovative medicines to address health issues. That is why I voted in favour.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-618-500"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/96694.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Rolandas Paksas (EFD), </span></span>  <span class="italic">raštu</span><span class="bold">. -</span> Balsavau už šį pasiūlymą.</p>
<p class="contents">II Naujoviškų vaistų iniciatyva yra pagal Septintąją bendrąją programą sukurta jungtinė technologijų iniciatyva. Sveikintina, kad šioje iniciatyvoje daugiau dėmesio bus skiriama visuomenės sveikatai, o ne pasirengimo veikti konkurencinėje aplinkoje biomedicininiams moksliniams tyrimams. Manau, yra tikslinga praplėsti darbotvarkės turinį ir į jį įtraukti visą inovacijų ciklą.</p>
<p class="contents">Pažymėtina, kad ši naujoviškų vaistų iniciatyva suteikia galimybes tyrėjams iš įvairių sektorių, o taip pat pacientų organizacijoms, įsijungti į ambicingus projektus, skirtus naujoms žinioms, reikalingoms ateities vaistams, sukurti ir išbandyti. Kitas svarbus aspektas yra tai, kad pagal NVI vykdomų mokslinių tyrimų rezultatai bus naudingi visam Europos farmacijos sektoriui.</p>
<p class="contents">Atsižvelgiant į tai, labai svarbu užtikrinti, kad būtų vykdoma geriausia žiniomis paremta veikla, kuri paskatintų didesnes įplaukas ir didesnį pramonės konkurencingumą.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-619-000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/96948.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Gilles Pargneaux (S&amp;D), </span></span>  <span class="italic">par écrit</span><span class="bold">. –</span> J’ai voté en faveur de ce règlement qui proroge l’entreprise commune IMI dans le domaine des médicaments innovants («Initiative en matière de médicaments innovants 2 - IMI2»). Ce texte vise à créer une entreprise commune Médicaments innovants 2, («IMI2») pour une période allant du 1<span class="sup">er</span> janvier 2014 au 31 décembre 2024. L’EC IMI2 remplace la précédente EC IMI lancée au titre du septième programme-cadre.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-619-500"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/96755.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Sergio Paolo Francesco Silvestris (PPE), </span></span>  <span class="italic">per iscritto</span><span class="bold">. -</span> In materia di proprietà intellettuale permangono ancora diverse preoccupazioni tra le parti interessate, anche se il Parlamento europeo ha difeso fortemente il rispetto integrale delle regole di partecipazione. </p>
<p class="contents">Inoltre, il Parlamento ha accolto i timori delle parti interessate in merito alla mancanza di un significativo coinvolgimento della comunità di ricerca nella definizione delle agende strategiche di ricerca, fattore che invece dovrebbe essere determinante per la coerenza e la pianificazione strategica all'interno della sfida sanitaria.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-620-000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/97170.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Francisco Sosa Wagner (NI), </span></span>  <span class="italic">por escrito</span><span class="bold">. -</span> He votado en contra de las enmiendas para respetar el acuerdo interinstitucional adoptado, pero apoyo su contenido, en particular, en lo relativo a la mejora de la transparencia del funcionamiento de las empresas comunes.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-621-000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/119434.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Dubravka Šuica (PPE), </span></span>  <span class="italic">napisan</span><span class="bold">. -</span> Cilj ovog prijedloga javno-privatnog partnerstva je nova verzija Inicijative za inovativne lijekove koja će djelovati pod Okvirnim programom Obzor 2020. Tim prijedlogom teži se postizanju većeg učinka na istraživanje i inovacije pritom koristeći nekoliko instrumenta, uključujući javno-privatna partnerstva u ključnim područjima na kojima istraživanje i inovacije mogu pridonijeti širim ciljevima Unije u pogledu konkurentnosti, poticati privatne investicije i pomoći rješavanju društvenih izazova. Smatram da je potrebno unaprijediti proces proizvodnje lijekova podržati djelotvornija istraživanja te suradnju među akademskom zajednicom, malim i srednjim poduzećima i biofarmaceutskom industrijom, kako bi se isporučili bolji i sigurniji lijekovi za pacijente te zbog toga podržavam ovaj prijedlog. Mišljenja sam kako je najvažniji cilj zajedničkog poduzeća pridonijeti provedbi okvirnog programa Obzor 2020., jačati mogućnost sudjelovanja manjih sudionika i promicati uključivanje malih i srednjih poduzeća u svoje aktivnosti. Sve naše aktivnosti i aktivnosti ovog Zajedničkog poduzeća moraju nas voditi ka jednom cilju, a to je poboljšanje zdravlja i blagostanja građana Europske unije.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-621-500"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/96920.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Kay Swinburne (ECR), </span></span>  <span class="italic">in writing</span><span class="bold">. -</span> I strongly support and voted in favour of these proposed ‘Joint Technology Initiatives’ (JTIs) and ‘Public 2 Public Partnerships’ (P2Ps), as they have proven levels of research efficiency and effectiveness as well as attracting high industrial participation compared to other areas of the EU’s research programmes, particularly amongst SMEs. I am particularly pleased that attempts from both the lead PPE and S&amp;D negotiators to reduce substantially the money allocated to them from Horizon 2020 were defeated. I view the programmes as a key priority in driving long-term industry participation, and, as the funding models used under the proposals generate a greater contribution from industry than would be the case under the usual Horizon 2020 funding rules, the cumulative effect is more money spent on research. It was also important to ensure that the work programmes of each partnership met the criteria agreed under the overall Horizon 2020 legislation, in order to guarantee the consistency of research priorities. In order to guarantee full scrutiny and transparency of the public expenditure, Parliament insisted on separate discharge procedures for each programme.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-622-000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/29579.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Marc Tarabella (S&amp;D), </span></span>  <span class="italic">par écrit</span><span class="bold">. –</span> Nous avons déposé des amendements afin de renforcer la transparence et la responsabilité de la structure de gouvernance et des processus décisionnels de l'entreprise commune IMI, dans le but de réaffirmer la légitimité de l'entreprise commune et de garantir que tous les organes disposent des moyens adéquats pour remplir leurs responsabilités dans un secteur particulièrement sensible, au sein duquel l'intérêt public doit être le moteur de toutes les actions de l'IMI.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-623-000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/36281.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Silvia-Adriana Ţicău (S&amp;D), </span></span>  <span class="italic">în scris</span><span class="bold">. -</span> Am votat pentru propunerea de regulament privind întreprinderea comună referitoare la inițiativa privind medicamentele inovatoare 2. În vederea punerii în aplicare a inițiativei tehnologice comune privind medicamentele inovatoare se instituie întreprinderea comună IMI2, până la 31 decembrie 2024. Pentru a se ține seama de durata Programului-cadru Orizont 2020, cererile de propuneri în cadrul IMI2 ar trebui lansate cel târziu până la 31 decembrie 2020. În cazuri justificate corespunzător, cererile de propuneri pot fi lansate până la 31 decembrie 2021. </p>
<p class="contents">Întreprinderea comună IMI2 înlocuiește și urmează întreprinderii comune IMI si constituie un organism căruia îi este încredințată punerea în aplicare a unui parteneriat public-privat. Tranziția de la întreprinderea comună IMI la întreprinderea comună IMI2 ar trebui să fie aliniată și sincronizată cu tranziția de la cel de-al șaptelea program-cadru la Programul-cadru Orizont 2020 pentru a se asigura utilizarea optimă a fondurilor disponibile pentru cercetare. Sediul întreprinderii comune IMI2 este în Bruxelles, Belgia. Întreprinderea comună IMI2 ar trebui să ofere sprijin continuu programului de cercetare privind medicamentele inovatoare.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-624-000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/119431.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Ruža Tomašić (ECR), </span></span>  <span class="italic">napisan</span><span class="bold">. -</span> Inovativna inicijativa za lijekove (IMI) je najveće europsko javno-privatno partnerstvo s ciljem poboljšanja procesa razvoja lijekova za podršku razvoju boljih i sigurnijih lijekova za bolesnike. IMI podupire znanstvene projekte i gradi mreže industrijskih i akademskih stručnjaka u Europi koji će potaknuti inovacije u zdravstvu. Podržala sam proširenje područja primjene IMI-a na područja bioznanstvenih istraživanja i inovacija u kojima se pokazala dodana vrijednost . Područja bi bila u interesu javnoga zdravstva, u skladu s izvješćem Svjetske zdravstvene organizacije o prioritetnim lijekovima za Europu i svijet. Širim sudjelovanjem, uključujući smisleno uključivanje organizacija koje se bave istraživanjem, organizacija pacijenata i civilnog društva, pridonijelo bi se napretku razvoja novih pristupa i tehnologija za prevenciju, dijagnozu i liječenje bolesti sa snažnim posljedicama za javno zdravstvo.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-624-500"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/96802.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Jacek Włosowicz (EFD), </span></span>  <span class="italic">na piśmie</span><span class="bold">. -</span> Unia Europejska i sektor farmaceutyczny wesprą przedsiębiorców zajmujących się badaniami nad nowymi lekami. Komisja Europejska oraz Europejska Federacja Przemysłu i Stowarzyszeń Farmaceutycznych (EFPIA) w ramach programu „New Drugs for Bad Bugs” (nowe leki przeciwko złym wirusom) w ciągu najbliższych siedmiu lat na badania nad nowymi i skuteczniejszymi antybiotykami wydadzą blisko 224 mln EUR. Kto może startować po pieniądze? Szpitale, które mogą prowadzić badania kliniczne nad nowymi lekami fazy pierwszej, drugiej i trzeciej, uniwersytety medyczne, podmioty prowadzące badania kliniczne na zlecenie firm farmaceutycznych oraz małe i średnie przedsiębiorstwa, które będą prowadzić prace badawcze w ramach tworzonych konsorcjów.</p></td><td width="16"> </td></tr></table></td></tr></table><table width="100%" border="0" cellspacing="0" cellpadding="5"><tr class="footerdocwin"><td></td><td align="right"><a target="_blank" href="/legal-notice/en">Legal notice</a> - <a target="_blank" href="/privacy-policy/en">Privacy policy</a></td></tr></table></td></tr></table></body></html>
